Raffaele Colombo/LinkedIn
Jun 25, 2025, 15:39
Raffaele Colombo: Dato-DXd Now Approved for Patients with EGFR-mutated NSCLC
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks Inc., shared a post on X:
“Dato-DXd now approved for patients with EGFR-mutated NSCLC after EGFR-directed and platinum-based therapies!
Accelerated approval based on TROPION-Lung05 and TROPION-Lung01
ORR was 45% (95% CI: 35, 54) and median DOR was 6.5 months (95% CI: 4.2, 8.4)”
Later Raffaele Colombo shared this post, adding:
“Pooled analysis of EGFR-mutant NSCLC from TROPION-Lung05 and TROPION-Lung01 was presented at ESMOASIA24.”
Later he also added:
“I didn’t know dato-DXd was already approved in Russia for EGFR-mutant NSCLC patients…3 months ahead of the U.S.!”
More posts featuring Raffaele Colombo.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 17, 2025, 08:54
Jul 17, 2025, 08:50
Jul 17, 2025, 08:35
Jul 17, 2025, 08:34
Jul 17, 2025, 06:42
Jul 17, 2025, 06:21
Jul 17, 2025, 01:09
Jul 16, 2025, 20:36